Click here for slides on this topic


An injectable monoclonal antibody of the PCSK9 inhibitor class for the treatment of an inherited form of dyslipidemia called familial hypercholesterolemia (FH). Marketed as Praluent®.
The following content matched the glossary term: Alirocumab

Alirocumab Significantly Reduces LDL-C in High-Risk Patients in ODYSSEY FH I & FH II


The PCSK9 inhibitor, alirocumab, significantly reduced LDL-C in high-risk patients with heterozygous FH in ODYSSEY FH I & FH II; from ESC 2015

Slide Library Results

Search Results for: Alirocumab Slides Found: 0